- Home
- APRE vs RMCO Comparison
APRE vs RMCO Comparison
Compare APRE & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- RMCO
- Stock Information
- Founded
- APRE 2006
- RMCO 2021
- Country
- APRE United States
- RMCO United States
- Employees
- APRE N/A
- RMCO N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- RMCO Multi-Sector Companies
- Sector
- APRE Health Care
- RMCO Miscellaneous
- Exchange
- APRE Nasdaq
- RMCO Nasdaq
- Market Cap
- APRE 13.5M
- RMCO 14.9M
- IPO Year
- APRE 2019
- RMCO N/A
- Fundamental
- Price
- APRE $1.50
- RMCO $1.22
- Analyst Decision
- APRE Strong Buy
- RMCO
- Analyst Count
- APRE 2
- RMCO 0
- Target Price
- APRE $15.50
- RMCO N/A
- AVG Volume (30 Days)
- APRE 29.2K
- RMCO 46.5K
- Earning Date
- APRE 05-13-2025
- RMCO 05-23-2025
- Dividend Yield
- APRE N/A
- RMCO N/A
- EPS Growth
- APRE N/A
- RMCO N/A
- EPS
- APRE N/A
- RMCO N/A
- Revenue
- APRE $1,502,581.00
- RMCO $807,089.00
- Revenue This Year
- APRE N/A
- RMCO N/A
- Revenue Next Year
- APRE N/A
- RMCO N/A
- P/E Ratio
- APRE N/A
- RMCO N/A
- Revenue Growth
- APRE 157.63
- RMCO 65.21
- 52 Week Low
- APRE $1.41
- RMCO $0.70
- 52 Week High
- APRE $5.90
- RMCO $1.59
- Technical
- Relative Strength Index (RSI)
- APRE 27.07
- RMCO 65.32
- Support Level
- APRE $1.41
- RMCO $1.12
- Resistance Level
- APRE $1.59
- RMCO $1.28
- Average True Range (ATR)
- APRE 0.11
- RMCO 0.10
- MACD
- APRE 0.02
- RMCO 0.02
- Stochastic Oscillator
- APRE 18.60
- RMCO 83.56
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.